Category: Markets
Published: 2026-06-27T16:11:54.000Z
Palvella Therapeutics' Chief Operating Officer Kathleen Goin sold 4,302 shares worth $476,000 through a pre-planned trading arrangement, while retaining 17,219 options. The sale comes amid a 620% one-year stock surge driven by investor optimism about the company's QTORIN rapamycin therapy for rare skin diseases. The FDA recently granted rolling review for the drug's New Drug Application, with the company targeting NDA completion in H2 2026.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.